I Interested In Nor Cal Kaiser Patients Offered BCG/Anktive Treatment, Post FDA Approval, For Hi Grade Non Muscle Invasive Cancer.
Generally this seems to be much more effective for folks who are BCG non responsive within 6 months (or a year?) of induction. It was approved by the FDA in April 24.
Yes, the FDA approved the immunotherapy drug nadofaragene firadenovec (Anktiva) in April 2022 for treating BCG-unresponsive non-muscle invasive bladder cancer. Studies found it improved outcomes… read more